ResApp Health Limited announced that it has signed a non-exclusive, three-year binding letter of intent (LOI) with Philippines-based telehealth start-up Homify Corporation ("Homify") under which Homify will integrate ResApp's smartphone-based acute respiratory diagnostic test ResAppDx into their telehealth services. Homify plans to launch ResAppDx on its platform in the middle of this calendar year. Homify was founded in 2021 by Wilson, Wayne and Rachelle Uy.

Wilson is also the founder of Kaching Technologies AI, a Philippine company that is a product reseller of Augmented Reality, Artificial Intelligence and other technology solutions for businesses and consumers. The Homify platform will integrate digital diagnostic and patient support tools from inception, with ResAppDx being the foundational technology. The Philippines has a population of 112 million people with many people facing difficulties accessing health care.

ResAppDx is ResApp's acute respiratory diagnostic test that uses machine-learning technology to analyse signatures in cough sounds to diagnose respiratory disease using a smartphone's inbuilt microphone. It is CE Marked in Europe and TGA approved for ARTG (Australian Register of Therapeutic Goods) listing in Australia. The launch of ResAppDx on Homify's platform is dependent on ResApp obtaining regulatory approval as a medical device in the Philippines.

The LOI is also conditional upon Homify achieving certain milestones, including securing the necessary regulatory and legal approvals to operate a telehealth business in the Philippines. The LOI specifies pricing on a monthly subscription basis with tiered pricing based on number of tests performed per month. Revenue from the agreement cannot be estimated at this early stage as it is dependent on Homify's market penetration following launch.

Either party may terminate the LOI with 60 days notice.